科威爾(688551.SH):2022年度在功率半導體領域的客户有較大突破性進展
格隆匯4月24日丨有投資者向科威爾(688551.SH)提問:公司在繼中車之後,功率半導體領域進展如何?
科威爾回覆:隨着中車時代電氣訂單陸續完成交付並運行順利後,訂單示範效應逐步顯現,2022年度,公司在功率半導體領域的客户有較大突破性進展,多個頭部客户進行了樣機試用,部分頭部廠商已完成訂單轉換,部分仍在認證階段。2022年度,中車時代電氣訂單約佔功率半導體事業部訂單總額的20%左右,剩餘80%為新增的客户訂單。2023年公司也將進一步推進行業其他客户的樣機試用和訂單轉換。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.